Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of Sonelokimab in Hidradenitis Suppurativa
NCT07007637Phase 3Enrolling by invitation
- Sponsor
- MoonLake Immunotherapeutics
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- Recombinant Proteins and Enzymes, Nanobodies (VHH)
- Countries
- 16
01
Overview
A Phase 3 trial of sonelokimab in hidradenitis suppurativa (HS), sponsored by MoonLake Immunotherapeutics. Started Jun 2025; status: enrolling by invitation.
02
Drugs
sonelokimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07007637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07007637.